ZNF629

Across TCGA pan-cancer cohorts, ZNF629 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ZNF629 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ZNF629 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF629 expression acts as an unfavorable survival marker.

THYM, UCEC, and PAAD are the cancer types where ZNF629 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
PAAD	OS	Median	All	0.117	0.640	.007	9	view →
COAD	OS	Median	All	0.282	0.706	.018	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	DFS	Median	All	0.210	0.709	.010	6	view →
LUAD	DFS	Median	III,IV	0.036	0.673	<.001	6	view →
LIHC	OS	Median	All	0.242	0.690	.017	6	view →
KICH	DFS	Median	II,III,IV	0.102	0.775	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ZNF629–THYM (OS)

Open the THYM breakdown →